AOD-9604 research guide for Pyu. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Pyu quickly find that local retail options are virtually absent. The upside of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any local market ever offers. The key verification criteria for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide gives Pyu researchers the methodology to verify sourcing options methodically and source high-purity AOD-9604 with confidence.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Pyu studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at minute levels. Community reputation in research forums is a valuable complement to COA verification — vendors with multi-year positive track records have built their reputation on real product performance. Hold lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Pyu
COA-verified · International tracking · Research grade
AOD-9604 operates beyond the scope of approved drug regulation — researchers should understand that the known safety profile is based on preclinical evidence rather than regulated clinical data. Lyophilised AOD-9604 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no cost saving makes omitting this acceptable. Protocol documentation — keeping clear records of compound, timing, and method — is a research best practice for AOD-9604 that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
